Clinical trial
A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for…
NCT00000842 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000842 |
|---|---|
| Title | A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy |
| Official title | A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Peripheral Nervous System Disease |
| Intervention type | Drug |
| Interventions | Nerve Growth Factor, Recombinant Human |
| Enrollment | 270 |
| Completion | Feb 1, 1999 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 4, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: